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Abstract 
Study hypothesis: Selective activation or blockade of the prostaglandin (PG) F2α receptor (FP 
receptor) affects ectopic endometrial tissue growth and endometriosis development. 
Study finding: FP receptor antagonists might represent a promising approach for the treatment 
of peritoneal endometriosis.  
What is known already: Eutopic and ectopic endometrium from women with endometriosis 
exhibit higher expression of key enzymes involved in the PGF2α biosynthetic pathway. It has 
also been shown that the PGF2α-FP receptor interaction induces angiogenesis in human 
endometrial adenocarcinoma.  
Study design, samples/materials, methods: For this study, a mouse model of endometriosis was 
developed by inoculating human endometrial biopsies into the peritoneal cavity of nude mouse 
(n=15). Mice were treated with AL8810 (FP receptor antagonist), fluperostenol (FP receptor 
agonist) or PBS. Endometriosis like lesions were collected and analysed for set of markers for 
angiogenesis, tissue remodeling, apoptosis, cell proliferation and capillary formation using qPCR 
and immunohistochemistry. 
Main results and the role of chance: We found that selective inhibition of the FP receptor with 
a specific antagonist, AL8810, led to a significant decline in the number (p< 0.01) and size of 
endometriosis-like lesions (p<0.001), down-regulated the expression of key mediators of tissue 
remodelling (MMP9, p<0.05) and angiogenesis (VEGF, p<0.01) and upregulated the pro-
apoptotic factor (Bax, p<0.01) as compared to controls. Immunohistochemical analyses further 
showed a marked decrease in cell proliferation and capillary formation in endometrial implants 
from AL8810 treated mice, as determined by proliferating cell nuclear antigen (PCNA) and von 
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Willebrand factor (vWF) immunostaining, respectively. Moreover, Fluperostenol, a selective FP 
receptor agonist, showed the opposite effects. 
Limitations, reasons for caution: We carried out this study in nude mice, which have low levels 
of endogenous estrogens which mat affects the lesion growth. Caution is required when 
interpreting these results to women.  
Wider implications of the findings: This study extends the role of PG signaling in 
endometriosis pathogenesis and points towards the possible relevance of selective FP receptor 
antagonism as a targeted treatment for endometriosis.  
Large scale data: N/A 
Study funding and competing interest(s): This work was supported by grant MOP-123259 to 
the late Dr Ali Akoum from the Canadian Institutes for Health Research. The authors have no 
conflict of interest. 
Keywords: Endometriosis, Prostaglandins, PGF2α, FP receptor, AL8810, Fluprsostenol 
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Introduction 
Endometriosis is a chronic inflammatory disease affecting 6-10% of reproductive-age women. It 
is characterized by the presence of functional endometrial tissue outside the uterine cavity and is 
associated with pelvic pain, dysmenorrhea and infertility (Giudice, 2010, Macer and Taylor, 
2012). The most accepted explanation of the extra-uterine localization of endometrial tissue is 
mainly based on the common occurrence of retrograde menstruation, where menstrual 
endometrial tissue is disseminated into the peritoneal cavity via the Fallopian tubes and is capable 
of implanting and developing into endometriosis lesions (Sampson, 1927). Although the full 
range of mechanisms responsible for the development of endometriosis lesions remain to be 
clarified, a number of recent GWAS studies have highlighted genetic risk factors that may 
contribute to life-time risk (Rahmioglu, et al., 2014).  
Prostaglandins (PGs) are well-known regulators of signalling within the female 
reproductive tract and their roles in ovarian function, embryo implantation and menstruation are 
well described (Sales and Jabbour, 2003, Vilella, et al., 2013). PGs have also been implicated in 
endometrial pathologies such as endometriosis and endometrial cancer (Jabbour and Sales, 2004). 
In the female reproductive tract, the E and F series of prostanoids are synthesized from 
arachidonic acid via a series of oxidation steps involving cyclooxygenase (COX-1, -2) enzymes 
and the PG E and F synthases, respectively (Narumiya and FitzGerald, 2001). Notably the aldo-
ketoreductases AKR-1C3 and AKR-1B1, which have PGF synthase activities, have also been 
localised to the human endometrium (Fortier, et al., 2008). After biosynthesis, PGF2α is 
transported out of the cell by means of a carrier-mediated process where it exerts 
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autocrine/paracrine functions through a G protein receptor (GPCR)-mediated interaction (Chan, 
et al., 1998). The GPCR that binds human PGF2α, the FP receptor, has been cloned, and its 
activation leads to coupling of the G protein Gq, activation of phospholipase C (PLC) and release 
of inositol trisphosphate (IP3) and diacylglycerol (Abramovitz, et al., 1994).   
Endometriosis is a neuroinflammatory disorder associated with pain and infertility. It has 
been suggested that altered endometrial functions contribute both to the aetiology of the disorder 
and development of infertility (Macer and Taylor, 2012, Taylor, et al., 1999) . Notably ectopic, 
extra-uterine endometrial tissue found in lesions retain certain hallmarks of eutopic endometrium 
including a dependence on oestrogens for continued growth (Hudelist, et al., 2007). This 
observation has led to the adoption of hormonal suppression as a widely used medical therapy, 
however this can result in development of unacceptable side effects including a pseudo-
menopause (due to a hypo-oestrogenic environment) or pseudo-pregnancy (due to a progestin-
dominant environment) (Bulun, 2009). Although hormonal manipulations are often used as first-
line therapy as well as after surgery to prevent recurrence of symptoms, their long term use is 
associated with loss of bone density, low mood and increased risk for uterine and ovarian cancers 
(Swiersz, 2002, Vercellini, et al., 2014). Recurrence rates are 50%-60% within a year after 
cessation of hormone therapy (Guo and Olive, 2007, Kyama, et al., 2008) and there is therefore 
an urgent need to identify non-steroidal therapeutic targets for the treatment of endometriosis. 
Our recent findings suggested a significant deregulation of PGF2α biosynthesis and action 
in women with endometriosis at multiple levels (Rakhila, et al., 2013). These included an over-
expression of COX2, the inducible rate limiting enzyme in PG synthesis, in eutopic and ectopic 
endometrium of women with endometriosis and an up-regulation of AKR-1C1 in endometriosis 
lesions (Rakhila, Carli, Daris, Lemyre, Leboeuf and Akoum, 2013). In addition, PGF2α-FP 
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receptor interaction has recently been shown to induce angiogenesis in human endometrial 
adenocarcinoma (Sales, et al., 2005). The present study was therefore designed to investigate, 
using a heterologous mouse model of endometriosis, the impact of treatment with selective FP 
receptor modulators on ectopic endometrial tissue growth and endometriosis development. Our 
data suggest that treatment with FP receptor antagonists might represent a promising approach 
for the treatment of peritoneal endometriosis. 
 
Materials and Methods 
Human tissue resource 
Endometrial biopsies (n=3/patient) were obtained from five patients undergoing surgical 
explorative laparoscopy or hysterectomy for benign conditions (confirmed as not having 
endometriosis and not receiving anti-inflammatory or hormonal medication for at least three 
months before surgery). These patients signed an informed consent for a research protocol 
approved by Saint-François d’Assise Hospital ethics committee on human research (Laval 
University, Québec, Canada).  
Animal handling and treatment 
For this study, 15 six to eight week-old female athymic Nude-Foxn1nu mice (Harlan 
Laboratories, Indianapolis, IN, USA) were used. The protocol was approved by the committee of 
animal protection of Laval University and in-vivo experiments were performed according to the 
Canadian committee of animal’s protection (CPA) rules. Mice were housed under laminar-flow 
filtered hoods in rooms maintained at 28°C with a 12:12-hour light-dark cycle. Housing 
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materials, food, and water were sterilized before use. A schematic illustration of the experimental 
design is shown in Figure 1a.  Human endometrial tissue samples collected were placed in cold 
sterile PBS and dissected into small pieces (~1mm3) and labelled with 8x10-6 M 
carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE, Invitrogen, Burlington, ON, 
Canada) diluted in PBS for 20 min at room temperature. Tissue fragments were washed twice in 
PBS and labelling was confirmed by fluorescence stereomicroscopy (Carl Zeis, Germany) 
equipped with a fluorescein isothiocyanate (FITC) filter to detect the fluorescence of CFDA SE 
at ex465/em535. 
For induction of endometriosis mice, were given buprenorphine (1.68 g per mouse) by 
intradermal injection for analgesia, then anesthetized with a mixture of oxygen (1.5: l) and 
isoflurane (3% to 4%) (Abbot Laboratories, Saint-Laurent, Quebec, Canada). A small (1 cm) 
cutaneous and peritoneal incision was made in a sterile environment, and 0.1 mL of PBS 
containing 13 CFDA-SE labelled endometrial tissue fragments were injected into the peritoneal 
cavity using a micropipette (Essentially,  biopsy from 1 patient was chopped into 39 fragments). 
The incision was closed with Coated NB (polyglactin 910) sutures (Ethicon Johnson & Johnson, 
Markham, ON, Canada) for the peritoneal tissue and MikRon autoclip 9 mm (Clay Adam Brand, 
Sparks, MD, USA) for the cutaneous tissue. The mice did not receive any exogenous supply of 
estrogen and they were monitored daily for comfort, survival, and weight for 12 days after initial 
surgery. To manipulate FP receptors, the mice were treated with the FP antagonist AL8810 
[(5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-
prostadienoic acid] (Cayman Chemical Company, Ann Arbor, MI, USA) (Griffin, et al., 1999) or 
the FP receptor agonist Fluprostenol (Cayman Chemical Company) (Jin, et al., 2006). On day 12 
mice were injected intra-peritoneally with AL8810 (5 mg/kg), Fluprostenol (0.15 mg/kg) 
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(Glushakov, et al., 2013, Jin, Lu, Paoni and Yang, 2006) or PBS as a vehicle control. Additional 
daily injections were given on days 13-18 with daily monitoring of weight. On day 19 (Fig 1a) 
animals were anesthesized and then euthanized in an atmosphere saturated by CO2. The 
abdominal cavity was examined under a fluorescence stereomicroscope using Axiocam camera 
and Axiovisio Rel 4.8 software (Carl Zeis, Germany). The number of lesions/mouse was 
recorded and they were measured, and photographed before being recovered and processed for 
RNA or histology as detailed below. The area of lesion was measured using ImageJ software by 
multiplying the maximum and minimum diameter of the lesion. 
RNA extraction and qRT-PCR 
Endometriosis lesions were dissected under fluorescence stereomicroscopy from the surrounding 
tissue and RNA was extracted with Trizol reagent (Invitrogen) according to the manufacturer’s 
instructions. The total RNA concentration was measured by using a NanoDrop 
spectrophotometer and then RNA was reverse transcribed using random hexamers. qRT-PCR 
was performed using an ABI 7000 Thermal Cycler (Applied Biosystems, Foster City, CA). Each 
PCR reaction contained 2 µL of reverse transcriptase product, 0.5 µL of primer (final 
concentration, 0.1 mM), 12.5 µL of SYBR Green PCR Master Mix (Invitrogen) containing 
TaqDNA polymerase buffer, deoxynucleotide triphosphate mix, SYBR green I, MgCl2, and 
TaqDNA polymerase. Primers were designed with Primer Premier 5 software to cross intron-
exon boundaries, and specificity to human tissue was verified with Basic Local Alignment Search 
Tool (BLAST) (Table 1). Samples were tested in duplicate, and, for each reaction, negative 
controls without RNA or reverse transcriptase, RNA from mouse tissue (negative control) and 
RNA from endometrial tissue (positive control) were added.  
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Histology and Immunohistochemistry 
 Lesions were removed carefully and fixed in 10% formalin and then embedded into paraffin. 
Cryosections (5 µm) of paraffin embedded tissue sections were rehydrated and stained with 
hematoxylin and eosin. For immunostaining, endometriotic lesions were mounted on poly-L-
lysine–coated microscope glass slides and immunostained as described previously (Rakhila, 
Carli, Daris, Lemyre, Leboeuf and Akoum, 2013). The primary antibodies used were anti-vWF 
(Dako, Burlington, ON, Canada) (A0082, 1:100) and anti-PCNA (Dallas, TX, USA) (sc-25280, 
1:100). Tissue sections incubated without the primary antibody were included as negative 
controls. Secondary antibodies used were HRP-conjugated goat anti-mouse IgG Jackson (115-
035-146) (1:2,000 dilution in PBS/BSA/Tween) for PCNA and a biotin-conjugated goat anti-
rabbit IgG (E 0432, Dako) (1:2,000 dilution in PBS/BSA/Tween) for vWF. Microphotographs 
were captured using the Image Pro Express program (Meyer Instrument, Houston, TX, USA). 
 
Statistical Analysis 
Data related to the number and volume of lesions followed a nonparametric distribution and were 
analysed using Mann-Whitney U test. Data related to the weight of mice and qRT-PCR followed 
a Gaussian distribution and were analysed using ANOVA and Bonferroni test (GraphPad 
Software, San Diego, CA). Differences were considered as statistically significant using p < 0.05. 
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Results 
AL8810 and Fluprostenol treatments engender opposite effects on ectopic endometrial 
tissue growth 
The animals exposed to either AL8810 or Fluprestenol showed no signs of any discomfort or 
weight loss. The engraftment rate was similar in all control mice (5-6 implants survived out of 13 
fragments) and was not patient dependent. At the time of lesion recovery endometriotic-like 
implants were found scattered throughout the abdominal cavity of the mice. Initial examination 
revealed that lesions were smaller in AL8810-treated mice compared with those in fluprostenol- 
and vehicle-treated mice (Figure 1B). Histological evaluation of harvested lesions showed 
endometrial tissue composed of epithelial glands and compact stroma (Figure 2A). In mice 
treated with AL8810, endmetriotic tissue implants were small cystic structures with degenerating 
endometrial glands and scattered stromal cells, whereas in mice treated with Fluprostenol, 
endometrial tissue closely adhered to the host tissue and exhibited many well-defined, secretory 
and active endometrial glands and compact stroma. Mice treated with AL8810 developed fewer 
lesions and the lesions detected were smaller, compared with Fluprostenol treated mice or control 
mice, which clearly had larger, more and well defined endometriotic lesions. Statistical analyses 
showed that the mean number and size of endometriotic lesions were significantly decreased in 
AL8810-treated mice, compared to vehicle-treated control mice (p < 0.001 and p < 0.01 
respectively), but they were significantly increased in Fluprostenol-treated mice (p < 0.01 and p < 
0.001 respectively) (Figure 2B). Endometriosis lesions were found at several sites, including the 
peritoneum, intestines, peritoneal fat, liver and kidney. However, in AL8810 treated mice lesion 
development was limited only to the peritoneal fat. 
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Expression of PGE2 and PGF2α biosynthetic and catabolic enzymes are altered by AL8810 
and Fluprostenol treatments 
In lesions recovered from AL8810-treated mice, concentrations of COX2 mRNA were reduced 
compared to lesions from control mice (p < 0.05). Treatment with Fluprostenol significantly 
increased COX2 mRNA concentrations as compared to vehicle control (p < 0.01) (Figure 3A). 
Concentrations of COX-1 mRNA was not altered by either treatment (Figure 3B).  The 
expression of the PGF2α biosynthetic enzyme AKR-1C3 was significantly decreased in lesions 
from AL8810-treated mice (p < 0.01), but was significantly increased following Fluprostenol 
treatment (p < 0.01) (Figure 3C). However, the expression of AKR-1B1 did not show any 
significant changes in response to AL8810 or Fluprostenol (Figure 3D). Analysis of specific 
PGE2 biosynthetic enzymes showed that mPGES-1 and  mPGES-2 were down-regulated in 
lesions from AL8810-treated mice, but up-regulated in those from Fluprostenol-treated mice  as 
compared to controls (p < 0.05, p < 0.001) (Figure 3, E-F). Concentrations of 15-PGDH mRNA, 
the catabolic enzyme of PGE2 and PGF2α, were significantly up-regulated in lesions from 
AL8810-treated mice (p < 0.001), but significantly down-regulated in lesions from Fluprostenol-
treated mice (p < 0.01) as compared to controls (Figure 3H). 
 
AL8810 and Fluprostenol modulate the expression of tissue remodelling and angiogenic 
factors 
We next assessed the expression levels of MMP-9, an important tissue-remodelling factor that is 
up-regulated in active endometriotic lesions in women (Weigel, et al., 2012) and a mediator of 
PGF2α signalling pathway (Sales, List, Boddy, Williams, Anderson, Naor and Jabbour, 2005). 
Treatment of mice with AL8810 showed significantly down-regulated MMP-9 mRNA 
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concentrations as compared to control (p < 0.05). In contrast, Fluprostenol treatment up-regulated 
MMP-9 compared to AL8810 (p < 0.01) (Figure 4A). Our data further showed that AL8810 
treatment, up-regulated mRNA concentrations of TIMP-1, a natural tissue inhibitor of MMP-9 
(Brew and Nagase, 2010) as compared to vehicle control (p < 0.01), whereas Fluprostenol 
treatment caused a down-regulation of TIMP-1 mRNA levels (p < 0.01). (Figure 4B). We next 
assessed the expression of VEGF, a major angiogenic factor, that is up-regulated in human 
endometriosis lesions (Donnez, et al., 1998). Data displayed in Figure 4C showed that VEGF 
mRNA levels were significantly reduced in lesions from mice treated with AL8810 compared to 
vehicle-treated control mice (p < 0.01), but significantly increased in mice treated with 
Fluprostenol (p < 0.05). 
 
AL8810 and Fluprostenol alter the expression of survival/apoptotic factors in endometriotic 
lesions  
As shown in Figure 5, the mRNA expression level of Bax, a pro-apoptotic factor, was up-
regulated in endometriosis-like lesions from AL8810-treated mice (p < 0.01), but was down-
regulated in lesions from Fluprostenol-treated mice (p < 0.001) as compared with lesions from 
control mice treated with vehicle (Figure 5A). Conversely, treatment with AL8810 showed a 
down-regulation of mRNA levels of the anti-apoptotic factor Bcl-2. while it was up-regulated in 
mice treated with Fluprostenol compared to AL8810 mice (p < 0.05) (Figure 5B). 
 
Immunohistochemical analysis of proliferation and blood capillary formation 
Due to the limited number of endometriotic lesions from AL8810-treated mice, it was not 
possible to test every protein, so we focussed on a few key processes. Immunolocalisation of 
PCNA, a marker of cell survival and proliferation (Weigel, Kramer, Schem, Wenners, Alkatout, 
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Jonat, Maass and Mundhenke, 2012, Yu, et al., 1991), showed that numbers of PCNA positive 
cells were decreased in AL8810-treated lesions but increased in Fluprostenol-treated lesions 
compared with controls (Figure 6). We also immunolocalised vWF (Von Willebrand Factor), an 
endothelial cell marker, (Zanetta, et al., 2000) and found that the density of microvessels was 
increased in lesions from Fluprostenol-treated mice, while it was difficult to detect vWF positive 
cells in lesions from AL8810-treated mice (Figure 7). 
 
Discussion 
In our study, we used a heterologous model of endometriosis to investigate the effect of in-vivo 
manipulation of an FP-selective agonist (AL8810) and an FP-selective antagonist (Fluprostenol) 
on lesion size and the concentrations of key mRNAs within the human tissue. In control and 
fluprostenol treated mice, the engraftment of lesions was found to occur throughout the peritoneal 
cavity attached to the intestine, kidney, liver and peritoneal wall while the lesions found in 
AL8810 treated mice were mainly found in peritoneal fat.  Our data showed that AL8810 resulted 
in a marked diminution of the size and number of endometriosis-like lesions and significant 
changes in the mRNA expression of major molecular mediators of angiogenesis, tissue 
remodelling, apoptosis and PG biosynthesis, as well as inhibitory effects on markers of cell 
proliferation and development of micro-vessels in endometriotic implants. In contrast, 
Fluprostenol, had significant but opposite effects on these pathways and instead favoured cell 
proliferation, angiogenesis and the growth of endometrial implants.  
Cumulative evidence supports a significant role for PGs in the pathophysiology of endometriosis. 
Our previous data showed distinct expression patterns of PG biosynthetic enzymes in ectopic and 
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eutopic endometrial tissues of women with endometriosis and a marked increase in the 
expression levels of the rate-limiting COX2 and the specific terminal synthases for PGE2 
(mPGES-1, mPGES-2 and cPGES) and PGF2α (AKR-1C3) in endometriotic lesions (Rakhila, 
Carli, Daris, Lemyre, Leboeuf and Akoum, 2013). This is consistent with findings from other 
studies (Matsuzaki, et al., 2004, Ota, et al., 2001, Sun, et al., 2004), supporting an increase in 
local production of PGs in endometriosis tissue deposits. Elevated levels of PGE2 and PGF2α are 
also found in the peritoneal fluid of women with endometriosis (Dawood, et al., 1984). Although 
well recognised as major mediators of pain and inflammation, PGs have also been shown to exert 
a wide array of biological functions and to possess direct and indirect growth-promoting, 
angiogenic and tissue remodelling effects (Ricciotti and FitzGerald, 2011). Based on our 
evidence and that of other studies, we hypothesized that selective blockade of cell receptivity to 
PGs may represent an interesting treatment avenue for endometriosis. PGE2 has four known 
cognate receptors, namely EP1, EP2 EP3 and EP4, and recent studies have shown that targeting 
EP2 and EP4 may inhibit the growth and survival of human endometriotic cell in vitro (Lebovic, 
et al., 2013). PGF2α has only one known cognate receptor, the F-series-prostanoid (FP). 
Therefore, it is tempting to speculate that specific inhibition of PGF2α signalling via its specific 
receptor is more achievable as a potential therapeutic option.  
Extensive cell proliferation, tissue remodelling and angiogenesis and aberrant apoptosis 
occur at the ectopic sites where endometrial tissue deposits develop into endometriotic lesions.  
In this study, AL8810 down-regulated the expression of Bcl-2, which would have favoured cell 
survival, and concomitantly up-regulated the expression of Bax, a key pro-apoptosis regulatory 
protein (Basu and Haldar, 1998). Meanwhile, the FP agonist Fluprostenol displayed opposite 
effects both on Bcl-2 and Bax expression. Taken together our data suggests that blocking PGF2α 
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would favour cell death and endometriotic lesion regression. The finding of an increased 
expression of PCNA, a marker of cell proliferation (Yu, Hall, Fletcher, Camplejohn, Waseem, 
Lane and Levison, 1991), in the Fluprostenol-treated mice and a decreased expression of this 
marker in AL8800-treated animals is consistent with these data and suggests a plausible impact 
of FP antagonism on cell proliferation. 
Recently, a novel pro-angiogenic role for PGF2α has been described in endometrial 
adenocarcinoma (Sales, List, Boddy, Williams, Anderson, Naor and Jabbour, 2005).  This PG has 
been shown to activate inositol-1,4,5-triphosphate in autocrine and paracrine manners and 
thereby initiate ERK signalling via the activation of MMPs, transphosphorylation of epidermal 
growth factor receptor (EGFR) and release of VEGF, which promotes angiogenesis by acting on 
adjacent endothelial cells (Sales, et al., 2004). The involvement of MMPs and VEGF in the 
growth and neovascularisation of endometriotic lesions is well documented. These molecules 
show an up-regulated expression locally in endometriotic lesions and peritoneal macrophages as 
well as in the uterine eutopic endometrial tissue. Their levels are also elevated in the peritoneal 
fluid of women with endometriosis (Chung, et al., 2002, Collette, et al., 2006, Donnez, Smoes, 
Gillerot, Casanas-Roux and Nisolle, 1998). Our study showed that specific blockade of PGF2α 
signalling using a specific antagonist of its receptor decreased the expression of VEGF and 
MMP-9 in endometriotic lesions. Beyond its well-known proteolytic activity, MMP-9 is endowed 
with a variety of biological functions. This gelatinase is involved in extracellular matrix 
remodelling in the early angiogenic phase of vascular bud and sprout formation (van Hinsbergh 
and Koolwijk, 2008) and plays an important role in tumourigenesis and tissue invasion (Hua, et 
al., 2011). MMP-9 shows an increased expression in both ectopic and eutopic endometrial tissues 
of women with endometriosis, according to our and other previous studies, acts as a potent 
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mediator of inflammation (Bellehumeur, et al., 2005) and may contribute to endometriosis 
progression and dissemination (Chung, Lee, Moon, Hur, Park, Wen and Polan, 2002, Collette, 
Maheux, Mailloux and Akoum, 2006).  Interestingly, treatment with AL8810 resulted in a 
parallel up-regulation of TIMP-1, a natural tissue inhibitor for MMP-9, (Brew and Nagase, 2010) 
which suggests the induction of a disequilibrium that may promote endometrial tissue invasion 
and growth within the host peritoneal tissue and the development of new blood vessels. In 
keeping with these findings, immunohistochemical analyses revealed that AL8810 effectively 
attenuated angiogenesis in endometriotic lesions, as indicated by a marked reduction in vWF-
positive microvessels, and that Fluprostenol stimulated cell proliferation and capillary ingrowth.  
In this study, we demonstrated that specific blockage of PGF2α-FP receptor signalling 
acted both upstream by inhibiting the expression of the rate-limiting enzyme COX2 and 
downstream by down-regulating the expression of the specific terminal synthases of PGF2α 
(AKR-1C3) and PGE2 (mPGES-1, mPGES-2 and cPGES). Furthermore, this was paralleled by a 
significant increase in the PG catabolic enzyme 15-PGDH, thereby suggesting a catabolic shift 
that we propose leads to a diminution of PG levels. Interestingly, selective activation of cell 
signalling using a specific FP receptor agonist led to opposite effects on the PGF2α and 
PGE2 biosynthesis pathways. Our data suggest that PGF2α-FP receptor signalling influences the 
biosynthesis of PGE2 and points to a mutual regulatory mechanism between PGF2α and PGE2. 
This is consistent with previous cell signalling studies showing reciprocal crosstalk between the 
FP receptor and PGE2 receptor EP2 in endometrial cells (Abera, et al., 2010, Sales, et al., 2008) 
and some evidence that PGF2α and PGE2 can both activate the FP receptor. Our findings further 
suggest that the PGF2α-FP receptor signalling promotes ectopic endometrial tissue growth and 
make plausible the involvement of PGE2 signalling.  
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One limitation of our model is that the success rate for implant survival was not high. One 
explanation could be that nude mice have lower levels of endogenous estrogen. It is also 
important to note that nude mice do not have T or B cells but they do possess NK cells and 
macrophages (Budzynski and Radzikowski, 1994) that can exhibit a partial immune response to 
clear foreign tissue. 
Most current medical treatments of endometriosis inhibit the pro-proliferative impact of 
oestrogens on ectopic lesions via suppression of ovarian steroidogenesis using oral 
contraceptives, aromatase inhibitors or gonadotropin releasing hormone analogues. Although use 
of COX-2 inhibitors could be beneficial, their clinical application is of concern because of 
reported cardiovascular and gastro-intestinal side effects (Howes, 2007). Given the promising 
data obtained using our well validated mouse model, we speculate that selective inhibition of the 
action of PGF2α may represent an alternative targeted treatment for endometriosis.  
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Figure Legends 
 
Figure 1. A) Schematic illustration of the experiment design. Human endometrial tissue was 
inoculated into the peritoneal cavity of mice (n=15; 13 fragments/mouse from one patient) using 
a micropipette and left for 12 days before starting treatment. On days 12-19 AL8810, 
Fluprostenol or vehicle (PBS) was injected i.p once a day (n=5/group).  B) Representative images 
captured at time of cull from mice treated with AL8810, Fluprostenol or vehicle. Note presence 
of endometriotic lesions under bright field (arrows) and human tissue origin confirmed under 
fluorescence. 
 
Figure 2. A) Histological evaluation of endometrial implants from vehicle, AL8810 and 
Fluprostenol treated animals. B). Number and size of endometriosis-like lesions as determined at 
sacrifice in situ; error bars represent mean ± SD,  **, *** p < 0.01 and p < 0.001, respectively, as 
compared to the control group. EG = Endometrial Glands, scale bar = 200 µm. 
 
Figure 3. Real time PCR analysis of the expression of COX1 (A), COX2 (B), AKR-1C3 (C) 
AKR-1B1 (D), mPGES-1 (E), mPGES-2 (F), cPGES (G) and 15-PGDH (H) in endometriotic 
lesions. Lesions were harvested from mice treated with vehicle (control), AL8810 or 
Fluprostenol. mRNA concentrations were normalized to that of the house-keeping gene GAPDH. 
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Results were from 5 control mice, 5 mice treated with AL8810 and 5 mice treated with 
Fluprostenol. Data are mean ± SEM.  **, ***, p < 0.01 and p < 0.001, respectively. 
 
Figure 4. Real time PCR analysis of the expression of MMP9 (A), TIMP1 (B) and VEGF (C) in 
endometriotic lesions. Lesions were harvested from mice treated with vehicle (control), AL8810 
or Fluprostenol. mRNA levels were normalized to that of the house-keeping gene GAPDH. 
Results were from 5 control mice, 5 mice treated with AL8810 and 5 mice treated with 
Fluprostenol. Data are mean ± SEM. *, **, ***, p < 0.05, p < 0.01 and p < 0.001, respectively 
 
Figure 5. Real time PCR analysis of the expression of Bax (A) and Bcl-2 (B) in endometriotic 
lesions. Lesions were harvested from mice treated with vehicle (control), AL8810 or 
Fluprostenol. mRNA levels were normalized to that of the house-keeping gene GAPDH. Results 
were from 5 control mice, 5 mice treated with AL8810 and 5 mice treated with Fluprostenol. 
Data are mean ± SEM. *, **, p < 0.05 and p < 0.01 respectively 
 
Figure 6. Representative immunohistochemical staining of PCNA in endometriotic lesions from 
Vehicle, AL8810 or Fluprostenol treated mice. Sections from proliferative phase of human 
endometrium were used as a positive control and the same sections incubated without the primary 
antibody were used as negative control for immunostaining; scale bar = 20 µm. 
 
Figure 7. Representative immunohistochemical staining of vWF in endometriotic lesions from, 
Vehicle, AL8810 or Fluprostenol treated mice. Sections from human endometrium were used as 
a positive control and the same sections incubated without the primary antibody were used as 
negative control for immunostaining; scale bar = 20 µm. 
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Table 1. List of Primers 
Gene       Forward Primer  (5’-3’)                                Reverse Primer(5’-3’)  
Cox-1                 GACCCGCCTCATCCTCATAG            TTGGAACTGGACACCGAACA 
Cox-2                  TCCCTTGGGTGTCAAAGGTAA         AAAACTGATGCGTGAAGTGCTG 
mPGES-1           GGATGCACTTCCTGGTCTTC            TCACGGAGCGGATGGGT 
mPGES-2           CTCATCAGCAAGCGACTCAA           CACGCAGCACGCCATA 
cPGES-               AGCCTGCTTCTGCAAAGTG            TCCTCCGAGACAACTGAATG 
AKR-1C3           TGTATTGGGATTTGGCACCTA         CAACCTGCTCCTCATTATTGTAT 
AKR-1B1           TCGCAGCCAAGCACAAT                  CAACAAGGCACAGACCCTC 
15-PGDH           AAGCAAAATGGAGGTGAAGG    CCAACTATGCCATGCTTTGA  
MMP-9              TTGACAGCGACAAGAAGTGG           CCCTCAGTGAAGCGGTACAT 
TIMP-1        GAGAAGGAAGTGGACTCTGGAAAC     AAACTCTATATCCTTCTCAGGCC 
VEGF                 GCTCTACCTCCACCATGCCA         CACCACTTCGTGATGATTCTGC 
Bax                      TCAACTGGGGCCGGGTTGTC        CCTGGTCTTGGATCCAGCCCAAC 
Bcl-2                    GGCACACGCCCCATCCAGCC  GCCGGGGGCAGCCGGGGTCT 
GAPDH             CAGGGCTGCTTTTAACTCTGG        TGGGTGGAATCATATTGGAACA 
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